Treosulfan-based conditioning in 6 pediatric and adolescent patients with non-malignant diseases and haematological malignancies

被引：0
|
作者：
Sovinz, P. [1 ]
Schwinger, W. [1 ]
Lackner, H. [1 ]
Benesch, M. [1 ]
Strenger, V. [1 ]
Seidel, M. [1 ]
Urban, C. [1 ]
机构：
[1] Med Univ Graz, Graz, Austria
来源：
BONE MARROW TRANSPLANTATION | 2012年 / 47卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S384 / S384
页数：1
相关论文
共 50 条
  • [21] Treosulfan-based reduced toxicity regimen prior to allogeneic hematopoietic cell transplantation in non-malignant disorders.
    Wojnar, Jerzy
    Giebel, Sebastian
    Markiewicz, Miroslaw
    Krawczyk-Kulis, Malgorzata
    Wylezol, Iwona
    Stella-Holowiecka, Beata
    Kruzel, Tomasz
    Holowiecki, Jerzy
    BLOOD, 2006, 108 (11) : 402B - 403B
  • [22] Retrospective analysis of treosulfan-based conditioning in comparison with standard conditioning in patients with myelodysplastic syndrome
    I Hilgendorf
    D Wolff
    T Gromke
    R Trenschel
    A H Elmaagacli
    U Pichlmeier
    C Junghanss
    M Freund
    D W Beelen
    J Casper
    Bone Marrow Transplantation, 2011, 46 : 502 - 509
  • [23] TREOSULFAN-BASED CONDITIONING REGIMEN PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH HEMATOLOGICAL MALIGNANCIES IS NON TOXIC, BUT NOT MYELOABLATIVE
    Popova, N. N.
    Kuzmina, L. A.
    Parovichnikova, E. N.
    Drokov, M. Yu
    Vasilyeva, V. A.
    Mikhaltsova, E. D.
    Koroleva, O. M.
    Dubnyak, D. S.
    Savchenko, V. G.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2016, 61 (04): : 172 - 177
  • [24] Retrospective analysis of treosulfan-based conditioning in comparison with standard conditioning in patients with myelodysplastic syndrome
    Hilgendorf, I.
    Wolff, D.
    Gromke, T.
    Trenschel, R.
    Elmaagacli, A. H.
    Pichlmeier, U.
    Junghanss, C.
    Freund, M.
    Beelen, D. W.
    Casper, J.
    BONE MARROW TRANSPLANTATION, 2011, 46 (04) : 502 - 509
  • [25] Skin toxicity following treosulfan-thiotepa-fludarabine-based conditioning regimen in non-malignant pediatric patients undergoing hematopoietic stem cell transplantation
    Even-Or, Ehud
    Kohl, Shahar Altman
    Zaidman, Irina
    Stepensky, Polina
    Molho-Pessach, Vered
    PEDIATRIC TRANSPLANTATION, 2020, 24 (01)
  • [26] Treosulfan-Based Conditioning and Hematopoietic Cell Transplantation for Nonmalignant Diseases: A Prospective Multicenter Trial
    Burroughs, Lauri M.
    Nemecek, Eneida R.
    Torgerson, Troy R.
    Storer, Barry E.
    Talano, Julie-An
    Domm, Jennifer
    Giller, Roger H.
    Shimamura, Akiko
    Delaney, Colleen
    Skoda-Smith, Suzanne
    Thakar, Monica S.
    Baker, K. Scott
    Rawlings, David J.
    Englund, Janet A.
    Flowers, Mary E. D.
    Deeg, H. Joachim
    Storb, Rainer
    Woolfrey, Ann E.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (12) : 1996 - 2003
  • [27] Treosulfan-based conditioning in pediatric hematopoietic stem cell transplantation: a prospective study on treosulfan exposure and clinical outcome
    Stoep, E. V.
    ten Brink, M.
    Bertaina, A.
    Smiers, F.
    Bredius, R.
    Moes, D. J.
    Locatelli, F.
    Guchelaar, H-J
    Zwaveling, J.
    Lankester, A.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S113 - S114
  • [28] LONG-TERM RESULTS OF RANDOMISED PHASE 2 TRIAL TO COMPARE TREOSULFAN WITH BUSULFAN BASED CONDITIONING IN CHILDREN WITH NON-MALIGNANT DISEASES
    Beier, Rita
    Bader, Peter
    Styczynski, Jan
    Schulz, Ansgar
    Greil, Johann
    Reinhardt, Dirk
    Schulte, Johannes
    Fagioli, Franca
    Gruhn, Bernd
    Locatelli, Franco
    Piras, Simona
    Hoenig, Manfred
    Sedlacek, Petr
    Bonanomi, Sonia
    Zecca, Marco
    Caniglia, Maurizio
    Cesaro, Simone
    Gozdzik, J.
    Sykora, Karl-Walter
    Mielcarek-Siedziuk, M.
    Kalwak, Krzysztof
    BONE MARROW TRANSPLANTATION, 2024, 59 : 130 - 131
  • [29] Addressing inequity in access to palliative care for patients with non-malignant or benign haematological diseases
    Chan, Kwok Ying
    Gill, Harinder Singh Harry
    Yap, Desmond Y. H.
    LANCET HAEMATOLOGY, 2022, 9 (07): : E473 - E474
  • [30] Myeloablative conditioning for hematopoietic stem cell transplantation in patients with non-malignant diseases
    Ringden, O.
    Svenberg, P.
    Le Blanc, K.
    Mattsson, J.
    Remberger, M.
    BONE MARROW TRANSPLANTATION, 2006, 38 (04) : 321 - 322
12345